EastGate Pharmaceutical Token (EGP)

EastGate Pharmaceutical Token (EGP). Creating solutions to vital pharmaceutical problems by merging pharmacy with blockchain. EGP Token would be used to make payments in pharmaceutical stores across the world.

Whitepaper

Important By investing in this business you agree to ourDisclaimer. All information including our rating, is provided merely for informational purposes. CryptoTotem does not provide investment advice.

What is EastGate Pharmaceutical Token

EastGate Biotech Corp. is a dynamic biotech company concentrating on altering the delivery ways for well-known drugs, currently administered only by injections, to non-invasive (oral or sublingual) routes. We are developing a technology platform for enhanced drug delivery designed to provide alternative administration of known drugs with the goal of offering patient-friendly products to improve compliance and increase health benefits to fit today's health-conscious lifestyles. At the present time our technology focuses on the delivery of insulin via a liquid insulin mouth solution based on proprietary composition, but we believe that our technology may also be applicable to the delivery of other active pharmaceutical ingredients. We may also develop other novel formulations of pharmaceutical and natural products. The company has identified several biologically active existing molecules that address unmet needs of patients, especially those with ever-growing chronic conditions.

The company will focus on validating its delivery technology platform and determining different applications for expanding therapeutic treatments. The company intends to out-license different applications. We have not entered into any definitive agreements with respect to the foregoing and there is no guarantee that the Company will enter into such agreements on favorable terms or at all.

Our secondary goal is to leverage our technology for the oral delivery of other active pharmaceutical ingredients for the treatment of non-diabetes indications. If we are successful in obtaining regulatory approval, we may also out-license our intellectual property to other pharmaceutical companies.